Mesoblast (NASDAQ:MESO) Shares Gap Down – Time to Sell?

Mesoblast Limited (NASDAQ:MESO)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $11.20, but opened at $10.67. Mesoblast shares last traded at $10.75, with a volume of 25,582 shares traded.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Maxim Group upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Tuesday, September 24th. Jefferies Financial Group raised Mesoblast from a “hold” rating to a “buy” rating in a report on Thursday, August 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Mesoblast in a research note on Thursday, August 29th. Finally, StockNews.com downgraded shares of Mesoblast from a “hold” rating to a “sell” rating in a research note on Wednesday, September 4th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Mesoblast presently has an average rating of “Moderate Buy” and a consensus price target of $11.50.

Mesoblast Trading Down 6.1 %

The company has a fifty day moving average price of $10.01 and a 200 day moving average price of $8.02. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21.

Institutional Trading of Mesoblast

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Signaturefd LLC increased its stake in shares of Mesoblast by 128.7% in the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after buying an additional 3,099 shares during the period. Pine Valley Investments Ltd Liability Co bought a new stake in Mesoblast in the 2nd quarter worth $80,000. Perkins Coie Trust Co grew its holdings in Mesoblast by 15.0% in the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock worth $94,000 after acquiring an additional 1,500 shares during the last quarter. Rathbones Group PLC purchased a new position in shares of Mesoblast in the second quarter valued at about $95,000. Finally, Chapin Davis Inc. raised its stake in shares of Mesoblast by 50.0% during the second quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock valued at $102,000 after acquiring an additional 5,000 shares during the last quarter. Institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.